Foundry Partners’s Anika Therapeutics ANIK Stock Holding History

Foundry Partners’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-75,450	Closed	-$3.08M	–	373
2021 Q1	$3.08M	Sell	75,450 -2,930	-4%	-$111K	0.1%	235
2020 Q4	$3.55M	Buy	78,380 +2,885	+4%	+$109K	0.14%	203
2020 Q3	$2.67M	Buy	75,495 +190	+0.3%	+$6.86K	0.13%	209
2020 Q2	$2.84M	Buy	75,305 +11,735	+18%	+$387K	0.14%	197
2020 Q1	$1.84M	Buy	63,570 +38,680	+155%	+$1.56M	0.1%	229
2019 Q4	$1.29M	Sell	24,890 -14,725	-37%	-$855K	0.05%	304
2019 Q3	$2.17M	Sell	39,615 -15,300	-28%	-$786K	0.09%	251
2019 Q2	$2.23M	Sell	54,915 -475	-0.9%	-$17.3K	0.09%	249
2019 Q1	$1.68M	Buy	55,390 +50	+0.1%	+$1.71K	0.07%	286
2018 Q4	$1.86M	Sell	55,340 -1,075	-2%	-$38.8K	0.08%	274
2018 Q3	$2.38M	Buy	+56,415	New	+$2.23M	0.09%	268

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Foundry Partners's ANIK Position: Q2 2021 in Review

Foundry Partners sold out of Anika Therapeutics (ANIK) in Q2 2021, closing a stake of 75,450 shares — an estimated $3.08M sold.

Foundry Partners first reported a position in ANIK in Q3 2018 and held it in 11 quarters. The position peaked at $3.55M in Q4 2020. 139 funds tracked by Wall St. Rank hold ANIK as of Q2 2021.

Foundry Partners reported no remaining Anika Therapeutics position as of Q2 2021 after selling out during the quarter.
Foundry Partners sold 75,450 Anika Therapeutics shares in Q2 2021, an estimated $3.08M.
Foundry Partners first reported a position in Anika Therapeutics in Q3 2018 and held it in 11 quarters.
Foundry Partners's Anika Therapeutics position peaked at $3.55M in Q4 2020.
139 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2021.

Based on Foundry Partners's 13F filing for Q2 2021, filed 23 Jul 2021.